Anika Therapeutics, Inc. (ANIK)

Over the past six months, Anika Therapeutics' stock price has experienced fluctuations influenced by several events. The 52-week trading range for ANIK has been between $7.87 and $15.79, with the stock price around $14.28 to $14.54 as of late March 2026. Key events impacting the stock include the Q4 2025 earnings report, which showed flat year-over-year revenue, and the Q3 and Q2 2025 earnings reports, which showed revenue decreases. The company also faced production yield issues and received a deficiency letter from the FDA regarding CMC and clinical data for Hyalofast. As of late March 2026, Anika Therapeutics has a consensus rating of "Buy" or "Moderate Buy" from analysts, with a median price target of $19.89.

Explicit information detailing demand seasonality for Anika Therapeutics' products and services is not readily available. Some reports mention "favorable order timing" and "increased order demand in Q2 2024" in relation to international OA pain management revenue, suggesting some variability in demand. The nature of their products might imply a relatively steady demand rather than strong seasonality, though specific market dynamics could introduce fluctuations.

Anika Therapeutics, Inc. is a global joint preservation company focused on early intervention orthopedic care, operating in the Healthcare sector, specifically in the Biotechnology industry. The company develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair, leveraging its proprietary hyaluronic acid (HA) technology. Its major products include OA Pain Management products like Monovisc, Orthovisc, and Cingal, and Regenerative Solutions like Integrity, Hyalofast and Tactoset.

Anika Therapeutics is headquartered in Bedford, Massachusetts, United States, and has a global presence, operating in the United States, Europe, and internationally. Its Hyalofast product has a commercial footprint in approximately 15 countries, including Thailand, the United Arab Emirates, and Colombia.

Anika Therapeutics' brand reputation has seen both positive developments and challenges. The company has demonstrated strong international growth in its OA pain management portfolio and continued momentum with its Integrity product. However, a decline in OEM channel revenue, production yield issues, and the failure of the pivotal U.S. Phase III FastTRACK clinical trial for Hyalofast to meet its primary endpoints have presented challenges. Despite these challenges, analysts generally maintain a "Buy" or "Moderate Buy" rating for ANIK.

Anika Therapeutics has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 45.82% to 91.53% of the company's stock is held by institutional investors, while insiders hold around 5.31% to 9.64%. Major institutional owners include BlackRock, Inc., Caligan Partners LP, and Vanguard Group Inc. Farmaceutici Spa Fidia is noted as a significant individual shareholder.